Dr Jonathan O’Keeffe
CEO & Founder
Doctor of Medicine (Oxford), Machine Learning Engineer (UCL) & Neuroscientist (Cambridge)
As a practising neurologist, Jonathan saw that his impact in clinical practice was linear — you see one patient, you impact one patient, patient number doubles, impact doubles, and you start again. Instead, he wanted to combine his neurology and computer science background to impact deeper than he ever could using one discipline alone. Perfectly positioned to see the flaws in the system, and with the expertise to solve them, he set about building Machine Medicine – a company jam-packed with AI, clinical acumen, and brazen ambition.
Dr Weil is a Wellcome Trust Clinician Scientist and Honorary Consultant Neurologist at the National Hospital for Neurology and Neurosurgery. She runs clinics in Cognitive Disorders, Movement Disorders and General neurology and has a particular interest in hallucinations and cognitive disorders in Parkinson’s disease.
Dr Ishihara is an experienced real-world data scientist and strategist, people and change manager, matrix team manager, and development coach in training. Her passion is for improving human health through science, innovation, and collaboration. She has a growing interest in digital health technology and working directly with patients and caregivers.
Abbi is an ACA chartered accountant who began her career at PwC before transitioning to consulting for media, marketing, tech start-ups and various enterprises. She has since held positions in a multinational AIM-listed tech company and an omnichannel retailer. Abbi recently joined Tide, a fintech challenger bank, and contributed to the successful delivery of Tide’s winning BCR bid.
Dr Hauser provides expert evaluation and management for patients with Parkinson's disease and other movement disorders. His expertise includes clinical trial design and execution. He has authored or co-authored over 300 peer-reviewed papers and is a frequent consultant to the pharmaceutical industry. Dr Hauser's goal is to bring new treatments to patients with Parkinson's disease and other movement disorders to improve quality of life and stop disease progression.
Prof. Denison has a proven track record in developing and translating technologies for medical devices. He specializes in bioengineering technology with an emphasis on sensors, interface electronics, and control algorithms.
Prof. McIntyre has a BS and PhD in biomedical engineering from Case Western Reserve University. Additionally, he received postdoctoral training from Johns Hopkins University and Emory University, where he studied DBS. Currently, he is a professor of Biomedical Engineering and Neurosurgery at Duke University.